Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.
Brief Summary: Malignant ascites often has a profound impact on the quality of life of cancer patients. Current treatments,including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab for the palliation of malignant ascites might be a novel choice for refractory malignant ascites.